Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
1	18/LO/0508	241903	An Open-Label, Multicentre, Long-Term Follow-Up Study to Investigate the Safety and Durability of Response Following Dosing of a Novel Adeno-Associated Viral Vector (FLT180a) in Patients With Haemophilia B	19/02/2020	08/07/2020	15/05/2018	09/07/2020	09/07/2020	09/07/2020	13/07/2020	Please select	
2	20/EE/0135	282213	Multiarm Therapeutic study in pre-ICU patients admitted with COVID-19 - Repurposed Drugs (TACTIC-R)	22/06/2020	16/07/2020	06/05/2020	17/07/2020	17/07/2020	20/07/2020	01/10/2020	Neither	No patients presented due to the strict criteria eligibility initially
3	20/YH/0090	278137	AN OPEN-LABEL,MULTICENTER, ROLLOVER STUDYTO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OFGANTENERUMABIN PARTICIPANTSWITHALZHEIMER'S DISEASE	27/05/2020	12/08/2020	20/04/2020	14/08/2020	14/08/2020	17/08/2020	04/11/2020	Neither	This study deals with a rare disease no patient presented to the team until Q3
4	19/LO/1753	269460	A phase 2, ranodmised, double-blind, placebo controlled study to evaluate the safety, efficacy, pharmacodynamics, and pharmacokinetics of SAR339375 for subutaneous injection administered every week in patients with Alport Syndrome	29/06/2020	21/07/2020	13/02/2020	20/07/2020	03/08/2020	03/08/2020	20/08/2020	Please select	
5	17/WA/0155	223941	Primary care Management of lower Urinary tract Symptoms in men: Development and validation of a diagnostic and decision-making aid.	21/01/2020	09/09/2020	23/08/2017	29/09/2020	29/09/2020	29/09/2020	10/12/2020	Neither	The team screened patients at the weekly clinic and intially no eligible patients were found until December
6	19/LO/1195	261755	A randomized, double-blind, placebo-controlled adjuvant trial in newly diagnosed primary glioblastoma subjects to assess the efficacy and safety of 2-hydroxyoleic acid (2-OHOA) in combination with radiotherapy and temozolomide standard of care treatment	17/08/2020	15/09/2020	05/12/2019	21/09/2020	28/09/2020	28/09/2020	04/11/2020	Please select	
7	20/NE/0058	275056	A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma (OLIE)	23/07/2020	21/08/2020	30/04/2020	03/09/2020	14/09/2020	15/09/2020	15/12/2020	Neither	Due to the nature of the disease criteria. This study focuses on relapsed osteosarcoma and we did not have any relapsed patients until December
8	19/NE/0357	271261	A Phase 3, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (NASH) The ARMOR Study	29/11/2019	30/07/2020	06/01/2020	31/08/2020	01/09/2020	01/09/2020		Sponsor	Because of the pandemic, the sponsor put on hold recruitment whilst they revised their protocol.

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
9	19/NI/0126	254829	SMALL: A Phase III, randomised, multi-centre trial addressing overtreatment of small screen-detected breast cancer by comparing standard surgery versus minimally invasive vacuum-assisted excision	09/03/2020	14/09/2020	15/10/2019	17/09/2020	18/09/2020	25/09/2020	25/03/2021	Neither	Delays with recruitment were due to the pandemic
10	19/LO/1949	274671	AN OPEN-LABEL, MULTI-CENTRE, PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF AUTO1, A CAR T CELL TREATMENT TARGETING CD19, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B CELL ACUTE LYMPHOBLASTIC LEUKAEMIA	06/08/2020	06/08/2020	17/02/2020	10/09/2020	14/09/2020	15/09/2020	28/09/2020	Please select	
11	19/SC/0107	237804	A phase II trial assessing nivolumab in strong class II expressing microsatellite stable colorectal cancer	04/08/2020	04/08/2020	05/07/2019	18/09/2020	21/09/2020	21/09/2020	15/10/2020	Sponsor	Initial delays were due to contracting delays within the sponsor company
12	20/YH/0174	283089	A randomised, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.	11/06/2020	29/07/2020	20/05/2020	01/09/2020	02/09/2020	02/09/2020	03/11/2020	Neither	No patients seen initially due to COVID-19 and the strict eligibility criteria
13	19/LO/0062	255909	A StuDy eVAluatiNg the EffiCacy and Safety of RalinEpag To Improve Treatment OUTCOMES in PAH Patients	11/12/2019	24/09/2020	03/04/2019	13/10/2020	15/10/2020	15/10/2020	19/05/2021	Neither	No patient were identified initially because of COVID however, two patients were identified in May 2021 and awaiting to achieve stable background treatment to make them eligible for the protocol. This strategy has been communicated and agreed with Sponsor
14	19/LO/0063	255904	A StuDy EVAluatiNg the Long-Term EffiCacy and Safety of RalinEpag in Subjects with PAH via an Open-Label EXTENSION	11/02/2019	24/09/2020	04/04/2019	13/10/2020	15/10/2020	15/10/2020		Neither	This study is a sub study and as there are no patients in the main study ADVANCE 301 and we are unable to recruit however, two patients identified are awaiting to achieve stable background treatment to make them eligible for the protocol. This strategy has been communicated and agreed with Sponsor
15	19/NW/0046	227794	A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumour DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma	11/05/2020	25/09/2020	26/03/2019	29/09/2020	01/10/2020	13/10/2020		Neither	This study deals with rare patients and none have been identified that meet the strict eligibility based on their liver function
16	19/YH/0222	252494	Positional Therapy for Obstructive Sleep Apnoea: a Randomised Controlled Trial to assess the effect on Health and Wellbeing in Older and Younger People.	05/03/2020	12/08/2020	24/07/2019	13/10/2020	13/10/2020	14/10/2020	25/11/2020	Neither	Initial set up was suspended due to COVID-19

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
17	18/YH/0358	242342	A randomised controlled trial to establish the clinical and cost effectiveness of expectant management versus pre-operative imaging with Magnetic Resonance Cholangiopancreatography (MRCP) in patients with symptomatic gallstones undergoing laparoscopic cholecystectomy at low or moderate risk of common bile duct stones	02/03/2020	02/10/2020	12/12/2018	02/10/2020	02/10/2020	06/10/2020	26/11/2020	Please select	
18	19/NE/0361	272352	A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of VIB4920 in subjects with Sjogren's Syndrome (SS)	21/07/2020	21/07/2020	15/01/2020	20/08/2020	15/10/2020	15/10/2020		Sponsor	Initial set up was suspended due to COVID-19. A contract amendment is still going through to change elements of the protocol causing delays to patient recruitment
19	20/EE/0031	275993	Randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate efficacy and safety of BAY 2433334 in patients following an acute non-cardioembolic ischemic stroke	21/01/2020	03/08/2020	03/04/2020	16/10/2020	20/10/2020	20/10/2020	31/12/2020	Sponsor	Initial delays were caused by contracting delays with the sponsor then greenlight was not given until November. Study opened to recruitment early December 2020
20	20/NE/0052	277285	Elite Study	17/09/2020	21/10/2020	15/04/2020	27/10/2020	27/10/2020	29/10/2020	08/12/2020	Please select	
21	19/NE/0263	261557	Open label, long-term safety, tolerability, and efficacy study of GIVINOSTAT in all DMD patients who have been previously treated in one of the GIVINOSTAT studies.	27/02/2020	14/09/2020	04/03/2020	20/10/2020	21/10/2020	21/10/2020	11/11/2020	Please select	
22	20/NE/0189	280542	Feasibility study for identification of patients at potential risk of silent aspiration in an acute stroke setting: a comparison of clinical swallow examination and cough reflex testing	05/03/2020	30/10/2020	17/09/2020	30/10/2020	30/10/2020	30/10/2020	05/11/2020	Please select	
23	20/LO/0828	279777	Master protocol of two randomized, double-blind, placebo controlled, multi center, parallel-group studies of dupilumab in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment in patients naïve to omalizumab and in patients who are intolerant or incomplete responders to omalizumab	04/08/2020	29/09/2020	09/07/2020	14/10/2020	16/10/2020	16/10/2020		Neither	The study nationally is struggling to recruit its first patient, due to a 4 month washout period and short recruitment period. However, this has now been extended and we hope to have the first patient soon. Patient population for this condition and relevant inclusion/exclusion criteria is small
24	20/EE/0170	1003070	Multicenter, randomized, placebo controlled, double-blind, parallel group, dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction	28/09/2020	28/09/2020	29/07/2020	13/10/2020	16/10/2020	16/10/2020	26/11/2020	Please select	
25	20/YH/0231	284781	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA	02/10/2020	20/10/2020	10/09/2020	20/10/2020	20/10/2020	21/10/2020	29/10/2020	Please select	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
26	19/EE/0362	272768	A Randomised Multiple Centre Trial of Conservative versus Liberal Oxygenation Targets in Critically Ill Children (Oxy-PICU)	15/10/2020	15/10/2020	23/12/2019	20/10/2020	21/10/2020	21/10/2020	29/10/2020	Please select	
27	20/HRA/4788	288786	A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19	12/10/2020	19/10/2020	05/10/2020	20/10/2020	20/10/2020	20/10/2020	29/10/2020	Please select	
28	19/LO/1652	271917	Phase 3, open-label, single arm study to evaluate efficacy and safety of FIX gene transfer with PF-06838435 (rAAV-Spark100-hFIX-Padua) in adult male participants with moderately severe to severe hemophilia B (FIX:C≤2%) (BeneGene-2)	29/10/2020	30/10/2020	28/01/2020	09/11/2020	09/11/2020	10/11/2020		Neither	Newcastle was the infusion site for a patient being recruited at Glasgow. The reason for delay of a patient entering the study, was due to the escalating COVID pandemic and in the intervening time things have improved and Glasgow have been able to set up to perform the infusion themselves
29	20/SC/0027	271232	A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101	30/03/2020	13/10/2020	06/04/2020	11/11/2020	17/11/2020	17/11/2020		Sponsor	Delays to recruitment have been caused by the sponsor confirming the finer details of an amendment
30	20/NW/0310	267092	A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease (CVD).	14/11/2019	12/10/2020	24/09/2020	04/11/2020	04/11/2020	04/11/2020	04/12/2020	Please select	
31	10/H0803/121	53663	Genetic Linkage Evaluation in Inherited C ardiac Conditions	30/06/2020	09/07/2020	08/01/2020	19/11/2020	20/11/2020	20/11/2020	10/02/2021	Neither	Initial set up was suspended due to COVID-19. No patients were identified until February 2021 due to the strict inclusion criteria
32	19/LO/0213	256261	A Phase 1 Trial of the combination of PS101-Mediated Acoustic Cluster Therapy (ACT) with Chemotherapy for the Treatment of Liver Metastasis in Patients with Solid Tumours with an Expansion Cohort in Metastatic Colorectal and Pancreatic Cancer	16/10/2020	20/10/2020	07/05/2019	22/10/2020	22/10/2020	03/11/2020		Neither	This study is not formally open at Newcastle, as COVID has delayed the Royal Marsden NHS finishing the first bit of dose ending.
33	20/YH/0317	288552	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	17/09/2020	18/11/2020	10/11/2020	19/11/2020	20/11/2020	20/11/2020	01/12/2020	Please select	
34	19/NE/0310	263546	A Phase IIb double-blind, randomised, placebo-controlled, multi-centre, confirmative three-way cross-over study on cognitive function with two doses of KH176 in subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation	26/10/2020	26/10/2020	31/03/2020	18/12/2020	30/12/2020	30/12/2020	17/03/2021	Both	Initial delays were caused by contacting problems within the NHS and Sponsor provider. Considerable delays to recruitment were due to facilitation of tests at site and then prolonged wait times between screening and return of invetigational results to validate proceeding to dosing

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
35	19/LO/1926	274398	A Phase 1/2 Open Label Study to Assess the Safety and Efficacy of UCB6114 Administered Intravenously to Participants with Advanced Solid Tumors	11/02/2020	17/11/2020	19/02/2020	08/12/2020	09/12/2020	09/12/2020	02/03/2021	Neither	As this study is a phase I dose finding study and first allocated slots on a cohort were not until the site opened. The cohorts were slow for the first 'sentinel' patient and it was not Newcastle's turn to treat first, causing delays to the first recruit at this site
36	20/LO/0731	279972	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis	13/05/2020	25/11/2020	25/06/2020	16/12/2020	16/12/2020	17/12/2020	30/06/2021	NHS Provider	Delays to recruitment has been caused by the loss of a research nurse and the study needs two. A nurse has been employed and will start with the study team in the near future
37	20/SC/0031	275229	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis	27/11/2020	27/11/2020	26/06/2020	16/12/2020	17/12/2020	17/12/2020		NHS Provider	Staff capacity issues caused delays in receiving the sponsor's green light to commence recruitment. Global rectuitment ended prior to staff capacity issues were resolved at this site
38	20/EE/0118	283014	COG-UK HOCI study	09/09/2020	07/12/2020	15/06/2020	07/12/2020	07/12/2020	07/12/2020	15/12/2020	Please select	
39	20/EM/0142	282923	Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus (B-Clear)	15/09/2020	25/11/2020	16/07/2020	10/12/2020	14/12/2020	14/12/2020	21/01/2021	Please select	
40	18/WM/0270	239150	TWIST – Trial of Wound drain In Surgical site infection in kidney Transplant	15/10/2020	15/10/2020	15/11/2018	24/11/2020	01/12/2020	01/12/2020	06/01/2021	Sponsor	Contracting delays within sponsor company
41	20/WM/0054	264593	CRAFFT – Children's Radius - Acute Fracture Fixation Trial: A multi-centre prospective randomised non-inferiority trial of surgical reduction versus non-surgical casting for displaced distal radius fractures in children.	16/10/2020	16/12/2020	16/04/2020	18/12/2020	18/12/2020	18/12/2020	20/03/2021	Neither	Recruitment was delayed due to COVID and fewer than usual children's fractures have been seen this year due to children not playing out due to the pandemic
42	20/NE/0032	273692	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER	07/09/2020	01/10/2020	28/07/2020	09/10/2020	09/10/2020	09/10/2020		Neither	A change in population due to COVID 19 caused delays to recruitment. The site closed to recruitment in March 2021 and failed to recruit any patients. Due to coronavirus the patients were presenting with more advanced disease and poorer performance status than would be eligible for the study.
43	20/LO/0453	1003010	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN STUDY PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA	15/09/2020	15/09/2020	29/04/2020	27/10/2020	28/10/2020	28/10/2020	10/06/2021	NHS Provider	Contracting delays within the Trust. Recruitment delays have been caused by the loss of a research nurse and the study needs two. A research nurse has been employed and will start with the study team to recruit in June 2021
44	18/SW/0130	246372	Prospective Evaluation of Thin-strut Biodegradable Polymer-coated Supraflex Sirolimus-Eluting Stents in an All-comers Patient Population (S-FLEX UK-II)	16/05/2018	08/12/2020	29/06/2018	11/01/2021	12/01/2021	13/01/2021	26/01/2021	Please select	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
45	19/NW/0571	261307	An adaptive, Phase 2 randomised double-blind, placebo-controlled multi-centre study to evaluate the safety and efficacy of multiple LOU064 doses in patients with moderate to severe Sjögrens syndrome (LOUiSSe)	24/09/2019	16/12/2020	06/01/2020	18/12/2020	18/12/2020	11/01/2021		NHS Provider	There was delays with the pharmacy green light and the Part 1 cohort needed to have completed recruitment before Newcastle were able to start with this study cohort.
46	19/LO/0712	257246	IP4- CHRONOS: Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer	08/01/2021	08/01/2021	07/08/2019	25/01/2021	25/01/2021	25/01/2021	17/05/2021	Neither	This is a difficult study to recruit to as two of the three treatments are available outside the trial and patients have quite often had strong opinions about their treatment
47	20/SC/0223	279425	Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants with Primary Biliary Cholangitis	14/12/2020	14/12/2020	08/07/2020	15/01/2021	25/01/2021	25/01/2021	19/03/2021	Neither	Set up was initially delayed due to COVID-19 however, once Newcastle received the green light on 25/02/2021 study information was sent out to patients. As soon as consent was received staff booked their screening and Newcastle recruited the first 2 patients in the UK on 19/03/2021
48	20/NW/0312	284188	A Registry-based, Randomised, Double-blind, Placebo-Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Heart Failure or Cardiovascular Death in Patients without Diabetes with Acute Myocardial Infarction at Increased Risk for Subsequent Development of Heart Failure	07/09/2020	08/12/2020	23/07/2020	21/01/2021	21/01/2021	25/01/2021	10/06/2021	Sponsor	Initial delays were caused by contracting delays with the sponsor.The research team are also waiting for IP shipment. Once the IP has been acknowledged in IWRS the sponsor will activate Newcastle to begin recruitment
49	20/NW/0383	287807	A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting	22/12/2020	22/12/2020	23/10/2020	22/01/2021	22/01/2021	25/01/2021		Sponsor	This COVID-19 Study was discontinued by sponsor in light of recent advances, the primary unmet need for patients outside of the hospital setting is for convenient, effective therapies that can be easily administered at home.
50	20/SC/0303	1003379	A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MEDI3506 in Participants with a diagnosis of Chronic Obstructive Pulmonary Disease and a history of Chronic Bronchitis with a History of Moderate or Severe Acute Exacerbations Receiving Standard of Care Maintenance Therapy	22/12/2020	22/12/2020	09/10/2020	21/01/2021	22/01/2021	22/01/2021		Both	Initial delays were caused by post SIV set up issues with regards to study equipment. Then staff shortages have also impacted on the studies ability to recruit patients during the relevant period
51	20/WM/0220	285844	A Phase Ib/IIa, randomized, double-blind placebo-controlled, multicenter adaptive design clinical trial to evaluate the immune signature of the treatment with the Imotope™ IMCY-0098 and its effect on the preservation of beta-cell function in young adult and adolescent patients with a recent onset Type 1 diabetes	30/11/2020	30/11/2020	11/09/2020	08/01/2021	08/01/2021	25/01/2021	11/03/2021	Neither	This is a trial of a very bespoke immunotherapy for people with newly diagnosed Type 1 diabetes age 18-45. This means finding eligible subjects is a challenge. People are diagnosed with Type 1 diabetes - about 3 patients per month. The eligibility then requires them to have a specific antibody profile and the correct genetic type.

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
52	20/NE/0250	284888	A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis	30/10/2020	09/12/2020	27/11/2020	21/12/2020	21/12/2020	07/01/2021		Neither	This study has a strict inclusion criteria as the main requirement is for platelets above 100. No patient have been identified
53	20/HRA/5205	289098	A PHASE I/II RANDOMIZED, TWO PARTS, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF AN INACTIVATED, ADJUVANTED SARS-COV-2 VIRUS VACCINE CANDIDATE (VLA2001), AGAINST COVID-19 IN HEALTHY INDIVIDUALS	21/12/2020	21/12/2020	16/12/2020	02/01/2021	04/01/2021	04/01/2021	06/01/2021	Please select	
54	20/NE/0253	288479	COVID-NURSE: evaluation of the effects of a COVID-specific fundamental nursing care protocol compared to care as usual on experience of care for non-invasively ventilated patients in hospital with the SARS-CoV-2 virus: a randomised controlled trial.	05/01/2021	11/01/2021	11/11/2020	12/01/2021	12/01/2021	13/01/2021	07/04/2021	Sponsor	The remote SIV did not happen until 3rd March 2021. The study opened to recruitment on 22nd March and the team then actively looked for recruits
55	20/HRA/5234	290965	A randomised, double-blind, placebo-controlled, Phase III trial to determine the efficacy and safety of inhaled SNG001 for the treatment of patients hospitalised due to moderate COVID-19	14/01/2021	25/01/2021	09/11/2020	29/01/2021	29/01/2021	29/01/2021	15/02/2021	Please select	
56	19/SC/0094	240646	Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP	23/11/2020	23/11/2020	16/05/2019	05/02/2021	08/02/2021	08/02/2021		Sponsor	Intial delays were caused by sponsor query resolutions. This study deals with rare patients and none have been identified that meet the strict eligibility criteria’
57	19/LO/1892	272434	A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson's disease experiencing motor fluctuations (BouNDless)	13/09/2019	21/01/2021	21/01/2020	05/02/2021	09/02/2021	09/02/2021	21/06/2021	Sponsor	Delayed by sponsor because of freezer and used IMP vials and their storage. No patient consented until June 2021
58	19/NW/0135	252254	An International Randomised Clinical Trial of Therapeutic Interventions with the Potential to Improve Outcome in Adults with Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation	23/03/2020	14/01/2021	17/05/2019	20/01/2021	23/02/2021	24/02/2021		Neither	To be eligible for this trial patients have to have a specific diagnosis and donor combination. The relatively small number of allogeneic transplants Newcastle perform means there will always be peaks and troughs of eligible patients. The first person approached declined the trial.
59	20/NW/0177	1003027	Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer’s disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205.	20/04/2020	20/01/2021	12/06/2020	05/02/2021	05/02/2021	05/02/2021	15/04/2021	Neither	This study was only available to participants who had taken part in a previous study. Delays to recruitment were caused to their availability, medical staff availability and getting all in house documents/approvals in place

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
60	20/EM/0089	278775	A PHASE IB, OPEN-LABEL, NON-RANDOMIZED, MULTICENTER STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE OR RO7082859 IN COMBINATION WITH LENALIDOMIDE OR RO7082859 IN COMBINATION WITH OBINUTUZUMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA	10/08/2020	22/01/2021	30/07/2020	29/01/2021	29/01/2021	01/02/2021		Sponsor	The trial got green light from pharmacy on the 5th Feb and on the 30th March the team were told all screening slots had been filled and the study had moved to waitlist. Since then the team have been waiting on a new protocol amendment which adds 75 patient slots
61	20/NW/0300	285728	A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with nonrelapsing secondary progressive multiple sclerosis (HERCULES)	18/08/2020	16/12/2020	15/09/2020	04/02/2021	04/02/2021	05/02/2021		Neither	Initial set up was delayed due to COVID-19. This study has not yet recruited as it has extensive inclusion/exclusion criteria. Three patients have been identified but two have declined participation after reading PIS as they feel the study is too intensive, we are still waiting to hear from the third patient and are continuing to actively pre-screen
62	20/LO/0031	266400	Perinatal and 2 year neurodevelopmental outcome in late preterm fetal compromise: the TRUFFLE 2 Randomised Trial	14/09/2020	18/01/2021	04/02/2020	08/02/2021	03/02/2021	09/02/2021		Neither	No eligible participants seen during the reported period because of the strict participant eligibility criteria due to the small patient population
63	20/EM/0173	281569	Tapering of Biologics in Inflammatory Arthritis Patients in Remission	16/10/2020	10/11/2020	31/07/2020	19/02/2021	25/02/2021	25/02/2021		Sponsor	Sponsor contracting delays due to financial aspects. This is a pilot study and the recruitment rate is actually one of the outcomes. It has been flagged with consultant colleagues who would need to identify most patients, but we have had no referrals. General business will undoubtedly play a part, but the team are stepping up the recruitment strategy with posters in offices at telephone clinics and pre-screening clinic lists
64	20/LO/1128	288114	A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF therapy	05/02/2021	05/02/2021	03/12/2020	16/02/2021	17/02/2021	17/02/2021	21/04/2021	Neither	No eligible patients were identified
65	20/NE/0172	275551	A phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of PF-06939926 for the treatment of Duchenne muscular dystrophy	16/11/2020	29/01/2021	15/10/2020	04/02/2021	04/02/2021	04/02/2021	22/03/2021	Please select	
66	19/LO/0911	263607	A Phase 1/2 trial on the safety, tolerability, pharmacokinetics, pharmacodynamics and exploratory efficacy of DYN101 in patients ≥ 16 years of age with centronuclear myopathies caused by mutations in DNM2 or MTM1.	26/02/2021	26/02/2021	08/08/2019	24/03/2021	25/03/2021	25/03/2021		NHS Provider	Recruitment has been delayed due to pharmacy green light only been given for this study on the 16th July, 2021. Participants have been contacted and screenings is being planned in August 2021

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
67	20/SC/0007	264068	A PHASE I/II, MULTICENTER, OPEN-LABEL, MULTI-ARM STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF IDASANUTLIN IN COMBINATION WITH EITHER CHEMOTHERAPY OR VENETOCLAX IN THE TREATMENT OF PEDIATRIC AND YOUNG ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LEUKEMIAS OR SOLID TUMORS	11/02/2021	11/02/2021	21/02/2020	23/03/2021	23/03/2021	23/03/2021		Sponsor	This study deals with very rare Patients and the treatment cohort is paused pending a decision by the dose review. The team have not been able to screen however, they expect to open for recruitment soon and the team have been waiting to see a patient from Dublin
68	19/YH/0379	251669	A multi-stage randomised trial of durvalumab (Medi4736) with chemoradiotherapy with 5-fluorouracil and mitomycin C in patients with muscle-invasive bladder cancer	11/03/2020	28/01/2021	07/02/2020	03/03/2021	05/03/2021	11/03/2021		Neither	One eligible patient was approached who declined trial entry. The team are hoping to find another eligible patient soon
69	20/YH/0178	283168	A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared with Teriflunomide, in Participants with Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety.	11/06/2020	26/02/2021	29/07/2020	18/03/2021	19/03/2021	19/03/2021		Neither	This study is looking for a very niche group of patients which was highlighted to the sponsor throughout set-up. They are still confident they will recruit, but it does require finding an incident patient with the right criteria. They continue to look actively for a suitable person
70	20/SC/0288	281708	FORTIS: A Phase 1/2, Open-Label, Ascending-Dose Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT845, an AAV8-Delivered Gene Transfer Therapy in Patients with Late Onset Pompe Disease	04/09/2020	05/03/2021	15/01/2021	19/03/2021	23/03/2021	23/03/2021		Sponsor	Following confirmation of C&C the sponsor notified Newcastle of an amendment which had to be locally approved before they would issue green light. The team weren't able to proceed with study activation based on the approved version of the protocol that was in place when C&C was granted. The amendment was approved on 2nd June, and the team received sponsor green light on 8th June
71	18/LO/0045	233362	A PHASE Ib/II, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (MORPHEUS-LUNG)	08/09/2020	12/02/2021	08/02/2018	25/03/2021	30/03/2021	30/03/2021	07/05/2021	Sponsor	Contracting delays with sponsor company caused initial delays and no patient was seen who fitted the eligibility criteria
72	20/YH/0280	282001	A platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non small cell lung cancer	27/10/2020	25/02/2021	06/11/2020	12/03/2021	16/03/2021	17/03/2021	15/06/2021	Neither	No suitable patients were identified until June due the strict eligibility criteria
73	20/WA/0121	276396	British Heart Foundation Randomised Clinical Trial of Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation (BHF PROTECT-TAVI)	11/11/2020	05/02/2021	20/05/2020	09/03/2021	09/03/2021	11/03/2021		NHS Provider	The study cannot recruit until 10 patients (not participants) have received the device. As they are not part of the study and will be used as practice for the PI/Sub I's we are waiting for the PI to create an information sheet for these people before the team can start the study

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
74	20/LO/1234	290834	A randomized controlled trial to compare the safety and efficacy of sirolimus-eluting biodegradable polymer ultra-thin stent (SUPRAFLEX™ Cruz) and everolimus-eluting biodegradable polymer stent (SYNERGY™) in treatment for three-vessel coronary artery disease: Multivessel TALENT.	16/11/2020	22/02/2021	12/02/2021	25/03/2021	25/03/2021	25/03/2021	11/05/2021	Neither	No eligible patients were identified
75	19/LO/1866	270431	PlasmaLyte Usage and assessment of kidney Transplant Outcomes in children: the PLUTO trial	12/11/2020	17/12/2020	22/12/2019	19/01/2021	16/03/2021	16/03/2021		Neither	Set up was suspended initially due to COVID-19. The team did approach the first potential recruit some time ago, however the family unfortunately declined. This was reported back to the trial team. The next potential kidney transplant in a paediatric patient happens on 12/8 and the family and patient have agreed to participate. The team are in process of consenting formally
76	20/WA/0028	272436	Post-Market Registry in Europe for the Use of CardioCel®, CardioCel® Neo and CardioCel® 3D	04/12/2020	29/01/2021	17/03/2020	12/03/2021	16/03/2021	17/03/2021	12/04/2021	Sponsor	Contracting delays with sponsor company. The study opened on 17th March 2021 and recruited their first patient 26 days later.
77	20/EM/0284	288568	A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment with GSK3228836 followed by Pegylated Interferon Alpha 2a in Participants with Chronic Hepatitis B Virus (B-Together)	30/12/2020	26/02/2021	22/12/2020	15/03/2021	17/03/2021	17/03/2021	28/04/2021	Please select	
78	18/LO/2033	252294	When to Induce Labour to Limit risk in pregnancy hypertension – a multicentre, randomised controlled trial	11/01/2021	23/02/2021	10/01/2019	08/03/2021	08/03/2021	11/03/2021		Neither	No eligible participants seen during the reported period because of the strict participant eligibility criteria due to the small patient population
79	20/EE/0239	281697	A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects with Prurigo Nodularis	12/01/2021	05/03/2021	29/01/2021	15/03/2021	16/03/2021	17/03/2021	03/06/2021	Neither	Patients sought but no eligible patients identified
80	20/NS/0128	276718	Clinical evaluation of an automated language transcription and analysis app to assist speech and language therapists with clinical decision making in the evaluation of developmental language disorders	12/01/2021	22/01/2021	08/01/2021	03/03/2021	12/03/2021	12/03/2021	27/04/2021	NHS Provider	Local Capacity and Capability review delays. Once this was resolved and the study opened the team sought eligible patients
81	20/WA/0203	281292	POLARx Cardiac Cryoablation system Post Market Clinical Follow-up study	02/02/2021	18/03/2021	10/08/2020	26/03/2021	29/03/2021	29/03/2021	14/04/2021	Please select	
82	20/NE/0178	269661	EXercise to Prevent frailty and Loss Of independence in insulin treated older people with DiabetEs: The EXPLODE Trial	04/06/2018	11/11/2020	14/08/2020	18/02/2021	25/02/2021	25/02/2021		Neither	This study was delayed due to COVID-19 restrictions impacting on study timelines and staff availability. Recruitment has been difficult due to the COVID impact and running virtual rather than face to face clinics at the Diabetes Centre, making assessment of suitability very slow
83	19/LO/0236	230338	The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Registry-based Randomized Trial - The EFFORT Trial	19/09/2019	02/10/2020	05/07/2019	02/02/2021	03/02/2021	03/02/2021	13/04/2021	Both	Initial delays were caused by sponsor and trust over contracting problems. No patients were seen who was suitable for the study until April 2021

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
84	20/LO/0676	273137	Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4)	07/05/2020	10/12/2020	13/07/2020	23/02/2021	22/02/2021	25/02/2021		Sponsor	Initial delays were caused by contracting delays with the sponsor. This study deals with a rare disease and has a strict inclusion criteria. The company announced that the drug did not work on less severe disease (F2-3) in a press release. Newcastle have delayed recruiting into this study until we were given sufficient information by the sponsor to determine if we wished to recruit our patients into the F4 study
85	20/LO/1107	258344	A pilot study to compare static night time Ankle Foot Orthosis (AFO) with Contracture Control Device (CCD) in the management of ankle contractures in ambulant boys with Duchenne Muscular Dystrophy (DMD).	01/04/2021	01/04/2021	01/03/2021	20/04/2021	21/04/2021	21/04/2021	06/05/2021		
86	19/WM/0364	257918	Letrozole or Clomifene, with or without metformin, for ovulation induction in women with polycystic ovary syndrome: a 2x2 factorial design randomised trial (The LOCI trial)	23/02/2021	23/02/2021	09/06/2020	14/04/2021	21/04/2021	21/04/2021	10/06/2021	Both	Delays intially were because of NHS Finance and sponsor answering finance queries. Other delays were caused by confirmation from sponsor for Green Light to recruit patients
87	20/LO/0181	275690	A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma	26/02/2021	22/03/2021	02/06/2020	26/04/2021	26/04/2021	26/04/2021	08/06/2021	Neither	No eligible patients were seen initially
88	19/LO/1381	257176	A Phase 4, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Chronic Migraine and Medication Overuse Headache	05/05/2020	14/01/2021	29/10/2019	20/04/2021	20/04/2021	21/04/2021	11/06/2021	Sponsor	Initial delays were caused by sponsor protocol amenedments. No eligible patient was seen until June 2021
89	20/NE/0264	286020	Post-Stroke rapid assessment of Cardiac arrhythmia evaluation- The Pace Study	23/02/2021	23/02/2021	10/02/2021	08/04/2021	08/04/2021	08/04/2021	21/04/2021	Both	Local capacity and capability reviews were not completed in time
90	20/LO/1021	283786	Randomised, double-blind, placebo-controlled, clinical study to evaluate the effect of opicapone 50 mg on Parkinson's disease patients with motor fluctuations and associated pain	16/11/2020	04/03/2021	16/10/2020	01/04/2021	08/04/2021	08/04/2021		NHS Provider	Due to Urgent public health studies that take priority at Newcastle the pharmacy team were unable to provide their greenlight until 30/06/2021

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
91	20/NE/0014	272055	Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms in Kawasaki disease (KD-CAAP: Kawasaki Disease Coronary Artery Aneurysm Prevention trial)	16/11/2020	26/02/2021	18/02/2020	30/04/2021	30/04/2021	30/04/2021		Both	Contracting delays between both parties meant the study was not granted approval in time. The KD-CAAP study has not yet been given the Green Light by sponsor. This study is researching a rare condition in the paediatric population.
92	20/SC/0433	282917	Wrist Injury Strengthening Exercise: a randomised multicentre feasibility study of resistance exercise versus usual care for optimising function after distal radius fracture in adults aged 50 years or over	24/02/2021	24/02/2021	05/01/2021	26/04/2021	26/04/2021	26/04/2021		Sponsor	Initial delays were caused by sponsor querying the protocol amendments. The reason this study has not recruited is due to mainly logistical issues. There have been changes to clinic times due to COVID-19 and we have not always had available staff to cover. There has also initially not been any eligible patients presented
93	20/WA/0266	285192	Prospective observational cohort study: To assess the utility of bio-degradable bile duct stent in the drainage of bile duct.	01/03/2021	01/03/2021	26/10/2020	20/04/2021	22/04/2021	22/04/2021		Sponsor	Initial delays were caused by sponsor querying the protocol amendments. Delays have also been caused because the indications for the use of the stents used in this study is limited. Identifying patients has been slow especially with COVID screening criteria for patients
94	20/SC/0334	287932	A Multicentre, Adaptive, Randomised, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalised Patients with COVID-19 Short Title: Therapeutics for Inpatients with COVID-19 (TICO) INSIGHT Protocol Number: 014 / ACTIV-3	12/03/2021	12/03/2021	30/09/2020	07/04/2021	13/04/2021	13/04/2021	06/05/2021	Please select	
95	21/SC/0119	297443	A single-blind, randomised, phase II UK multi-centre study to determine reactogenicity and immunogenicity of heterologous prime/boost COVID-19 vaccine schedules – Stage 2	24/03/2021	13/04/2021	12/04/2021	15/04/2021	16/04/2021	16/04/2021	20/04/2021	Please select	
96	19/NE/0145	254931	FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma	15/05/2019	19/03/2021	22/07/2019	12/05/2021	17/05/2021	17/05/2021	26/05/2021	Both	Contracting delays with costs caused the study to be delayed with approval
97	19/LO/0288	235544	A Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline with Standard Psychological Care for Depression in Parkinson's Disease	16/09/2019	23/02/2021	13/11/2019	18/05/2021	20/05/2021	20/05/2021	24/06/2021	Both	Delays were caused by contracting problems around the data sharing agreement alongside the standard contract
98	20/EM/0003	269023	Multicentre, open-label, randomised controlled trial of early surfactant therapy versus expectant management in late preterm and early term infants with respiratory distress.	08/01/2020	24/03/2021	14/02/2020	06/05/2021	07/05/2021	07/05/2021		Both	Initial delays were caused by the local capacity and capability review not being completed in time. Subsequent delays have been caused by a clarification and change of routine practice was needed regards to the saturation limits in the study. The registered nurse and PI also needing to self isolate which has delayed in the recruitment of patients to the study

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
99	21/SS/0013	271797	Pain Relief in Major Amputation (PRIMA): A randomised clinical trial comparing pre-incision 'single-shot' nerve block and continuous peri-neural catheter for patients undergoing a major lower limb amputation	30/04/2021	13/05/2021	15/03/2021	13/05/2021	14/05/2021	14/05/2021		NHS Provider	Set up has been delayed due to staff absences due to COVID isolation
100	19/EM/0357	270397	A Phase 2, Double-Blind, Randomized, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid, Administered Alone or in Combination with Bezafibrate, in Subjects with Primary Biliary Cholangitis who had an Inadequate Response or who were Unable to Tolerate Ursodeoxycholic Acid	07/12/2020	07/12/2020	29/11/2019	18/12/2020	20/01/2021	12/05/2021		NHS Provider	Initial set up was suspended due to COVID-19. The study still hasn't been given the green light from NHS pharmacy because of a backlog with the amount of studies needing pharmacy input
101	20/SC/0335	286668	An open-label, randomized study to assess the relative bioavailability (BA) and bioequivalence (BE) of fixed-dose combination (FDC) formulations of niraparib plus abiraterone acetate (AA) compared to niraparib and AA co-administered as single agents in men with prostate cancer	21/07/2020	01/03/2021	17/11/2020	21/05/2021	21/05/2021	24/05/2021		Sponsor	Delays were caused by contracting delays with sponsor. No patients have been identified that meet the strict eligibility criteria
102	20/NE/0283	286210	An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post Transplant Recurrence of C3G or IC-MPGN	27/07/2020	26/04/2021	04/02/2021	13/05/2021	13/05/2021	14/05/2021		Please select	
103	21/NE/0005	277964	The effect of residual beta-cell function on the glucose-lowering potential of mealtime whey protein supplementation in people with diabetes.	01/09/2020	04/05/2021	19/02/2021	19/05/2021	19/05/2021	19/05/2021		Please select	
104	20/NE/0270	286609	Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination with Talazoparib in Advanced Solid Tumors with ATR inhibitor Sensitizing Mutations	26/08/2020	09/04/2021	22/12/2020	07/05/2021	10/05/2021	10/05/2021	18/05/2021	Please select	
105	20/LO/0963	281310	Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)	07/09/2020	02/02/2021	23/10/2020	20/05/2021	21/05/2021	21/05/2021		Sponsor	Delays caused by contracting issues with sponsor - when study was submitted the sponsor was Seattle Genetics, company changed company name to SeaGen which required additional vendor assessments and finance reviews and assurances to be put into place, causing delays. Delays to recruitment have been caused by staffing within in the Cancer Team

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
106	20/WM/0195	268363	A multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide	20/11/2020	29/04/2021	25/09/2020	21/05/2021	24/05/2021	24/05/2021		Please select	
107	20/LO/1307	291610	A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients	20/04/2021	20/04/2021	08/02/2021	27/05/2021	28/05/2021	28/05/2021		Neither	No patients have been identified who meet the eligibility criteria
108	20/SC/0448	290709	Community participants with COPD or bronchiectasis and at risk of Respiratory Viral Infections including SARS-CoV-2: An open-label, multicentre feasibility study of an inhaled nitric oxide generating solution (RESP301)	14/04/2021	14/04/2021	18/12/2020	06/05/2021	07/05/2021	07/05/2021		Neither	No patients have been identified who meet the eligibility criteria
109	21/LO/0056	1003503	Interventional, randomized, double-blind, parallel-group, placebo-controlled delayed-start study to evaluate the the efficacy and safety of eptinezumab in patients with episodic Cluster Headache (eCH).	11/01/2021	06/05/2021	25/02/2021	24/05/2021	24/05/2021	24/05/2021		Please select	
110	21/WA/0008	283679	A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATORCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL OR HEMIRETINAL VEIN OCCLUSION	23/02/2021	20/04/2021	26/03/2021	21/05/2021	21/05/2021	21/05/2021			
111	20/EM/0237	266746	Acceptance and Commitment Therapy for Young Brain Tumour Survivors: An Acceptability and Feasibility Trial	22/03/2021	29/04/2021	24/11/2020	14/05/2021	14/05/2021	14/05/2021		Please select	
112	21/YH/0071	295903	Phase 2/3, Placebo-Controlled, Randomized, Observer-Blinded, Study to Evaluate to the Safety, Tolerability and Immunogenicity of SARS-CoV-2 RNA Vaccine Candidate (BNT162b2) against COVID-19 IN Healthy Pregnant Women 18 years of Age and Older.	24/03/2021	25/05/2021	21/04/2021	25/05/2021	25/05/2021	25/05/2021	24/06/2021	Please select	
113	21/NW/0125	294164	A RANDOMIZED, OBSERVER-BLIND, CONTROLLED, SUPERIORITY STUDY TO COMPARE THE IMMUNOGENICITY AGAINST COVID-19, OF VLA2001 VACCINE TO AZD1222 VACCINE, IN ADULTS	03/03/2021	30/04/2021	20/04/2021	06/05/2021	07/05/2021	07/05/2021	10/05/2021	Please select	
114	21/WA/0066	253665	A randomised crossover design study comparing the pharmacokinetics and pharmacodynamics of two single oral doses of aspirin (75 mg v150mg) in pregnant women at risk of pre-eclampsia.	07/08/2018	23/06/2021	30/03/2021	23/06/2021	25/06/2021	25/06/2021		Please select	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
115	19/SC/0599	270649	A Phase 1b Study of ASP1948, Targeting an Immune Modulatory Receptor, as a Single Agent and in Combination with Nivolumab in Subjects with Advanced Solid Tumours	26/04/2021	26/04/2021	03/03/2020	09/06/2021	15/06/2021	15/06/2021		Sponsor	Set up was delayed as the contracting team had to wait for sponsor to sign. No patients have yet been identified that meet the eligibility criteria
116	21/NE/0020	275595	A pragmatic, multicentre, placebo-controlled, 3-arm, double-blinded, randomised controlled trial, incorporating an internal pilot, to determine the role of bronchodilators in preventing exacerbations of bronchiectasis	11/11/2019	14/06/2021	10/03/2021	14/06/2021	14/06/2021	17/06/2021		Please select	
117	19/LO/1690	240451	Visualizing and Measuring Facial Expressions of Children with Cleft Lip using 3D Surface Data obtained from Depth Sensors	23/03/2021	24/03/2021	14/11/2019	01/06/2021	09/06/2021	09/06/2021		Sponsor	Initial delays were caused by the sponsor querying items within the contract. No patient have been identified that meet the eligibility criteria
118	19/LO/1585	263041	Compression Hosiery to Avoid Post-Thrombotic Syndrome	17/12/2019	03/06/2021	24/10/2019	24/05/2021	25/06/2021	29/06/2021		Please select	
119	21/LO/0186	286735	Effects of tele-rehabilitation multimodal lifestyle intervention on function capacity, cardiovascular health and quality of life inpatients with peripheral artery disease from low socioeconomic areas: a pilot randomized controlled trial Telehealth EXercise Training in peripheral arterial disease –The TEXT-PAD study	01/07/2020	06/05/2021	22/04/2021	05/08/2020	11/06/2021	11/06/2021		Please select	
120	20/NW/0260	1003209	A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation	20/01/2021	20/01/2021	17/07/2020	15/06/2021	21/06/2021	21/06/2021		Sponsor	The sponsor changed halfway throught the contract which caused huge delays. The study still hasn't been given the Green Light
121	20/NW/0340	1003335	A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS	22/09/2020	19/05/2021	18/09/2020	19/05/2021	20/05/2021	08/06/2021		Please select	
122	20/WS/0057	277361	Erythropoietin and Darbepoetin in Neonatal Encephalopathy (EDEN) study	20/10/2020	19/05/2021	27/05/2020	01/06/2021	02/06/2021	02/06/2021		Please select	
123	21/EM/0041	281071	Human Milk, Nutrition, Growth, and Breastfeeding Rates at Discharge: The Hummingbird Study	13/11/2020	20/05/2021	06/04/2021	01/06/2021	01/06/2021	01/06/2021	08/06/2021	Please select	
124	20/YH/0300	287046	A Prospective, Multi-Center Study of the Braive™ Growth Modulation System When Used in the Treatment of Pediatric Patients Diagnosed with Juvenile or Adolescent Idiopathic Scoliosis (BRAIVE IDE Study)	26/04/2021	09/06/2021	04/01/2021	11/06/2021	11/06/2021	14/06/2021		Please select	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Date site was invited	Date site was selected	HRA Approval Date	Date site was confirmed by sponsor	Date site was confirmed	Date site was ready to start	Date of the recruitment of first patient	Reasons for delay correspond to:	Comments
125	21/WM/0013	283141	Hysteroscopic Excision of Leiomyoma and Polyp in Infertility - two randomised controlled trials	21/05/2021	07/06/2021	10/02/2021	09/06/2021	09/06/2021	17/06/2021		Please select	
126	21/SC/0200	300677	A Phase II/III Partially Double-Blinded, Randomised, Multinational, Active-Controlled Study in Both Previously Vaccinated and Unvaccinated Adults Ages 30 and Above to Determine the Safety and Immunogenicity of AZD2816, a Vaccine for the Prevention of COVID-19 Caused by Variant Strains of SARS-CoV-2	15/06/2021	29/06/2021	22/06/2021	29/06/2021	29/06/2021	29/06/2021		Please select	
127	20/NE/0248	270777	Obeticholic acid for the Amelioration of Cognitive Symptoms trial - 1	13/09/2019	08/03/2021	19/01/2021	31/03/2021	01/04/2021	01/04/2021	24/06/2021	Neither	Delays to recruitment was caused because the patient needed an MRI scan as per protocol, and was booked into the first one that came available
128	21/YH/0026	289207	The HistoSonics System for treatment of primary and metastatic livertumors using histotripsy.	16/09/2020	24/05/2021	16/04/2021	24/05/2021	25/05/2021	09/06/2021		Please select	
129	20/LO/0821	281982	AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM GANTENERUMAB ADMINISTRATION IN PARTICIPANTS WITH ALZHEIMER'S DISEASE	18/08/2020	10/06/2021	23/07/2020	10/06/2021	18/06/2021	18/06/2021	30/06/2021	Please select	